BioMarin Pharmaceuticals
BMRN
557 hedge funds and large institutions have $15.5B invested in BioMarin Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 68 funds opening new positions, 197 increasing their positions, 192 reducing their positions, and 59 closing their positions.
15% more first-time investments, than exits
New positions opened: 68 | Existing positions closed: 59
1% more funds holding
Funds holding: 551 → 557 (+6)
3% more repeat investments, than reductions
Existing positions increased: 197 | Existing positions reduced: 192
0% more funds holding in top 10
Funds holding in top 10: 11 → 11 (0)
0.43% less ownership
Funds ownership: 95.63% → 95.21% (-0.43%)
7% less call options, than puts
Call options by funds: $148M | Put options by funds: $159M
11% less capital invested
Capital invested by funds: $17.4B → $15.5B (-$1.91B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$187M |
| 2 |
Barclays
London,
United Kingdom
|
+$99.4M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
+$46.7M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$41.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$33.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$78.4M |
| 2 |
Amundi
Paris,
France
|
-$69.3M |
| 3 |
BlackRock
New York
|
-$58.6M |
| 4 |
Jennison Associates
New York
|
-$46.7M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
-$42.6M |
BMRN Hedge Fund Activity: Q2 2023 in Review
557 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q2 2023, worth a combined $15.5B — down 11% from $17.4B a quarter earlier.
Buyers outnumbered sellers: 68 funds opened new BMRN positions and 59 closed out — a net gain of 9 holders — while 197 added to existing stakes and 192 trimmed.
The largest buyer was Viking Global Investors, adding an estimated $187M. The largest seller was Invesco, cutting an estimated $78.4M.
- 557 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q2 2023, up from 551 in Q1 2023.
- Funds reported $15.5B of BioMarin Pharmaceuticals stock for Q2 2023, down 11% quarter-over-quarter.
- 68 funds opened new BioMarin Pharmaceuticals positions in Q2 2023 and 59 closed out, a net change of +9 holders.
- The largest BioMarin Pharmaceuticals buyer in Q2 2023 was Viking Global Investors, an estimated $187M added.
- The largest BioMarin Pharmaceuticals seller in Q2 2023 was Invesco, an estimated $78.4M sold.
Based on aggregated 13F filings for Q2 2023.